If it is an object of your research division to find further indications for active substances already approved, it should always be checked whether the active substance with the new indication might qualify for Orphan Drug Status.
We are glad to check that for you, to prepare the Orphan Drug application, and to take care of the correspondence with EMEA or FDA (see Orphan Drug).
A patent application should be prepared contemporaneously to an Orphan Drug application which later provides a valuable combination for commercialization.